Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas

NCT04803201 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT04803201
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04803201 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase II Study of CHO(E)P vs CC-486-CHO(E)P vs Duvelisib-CHO(E)P in Previously Untreated CD30 Negative Peripheral T-Cell Lymphomas
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 2
Overall status
Recruiting
Start date
October 8, 2021
Completion date
May 19, 2027
Enrollment
170 (estimated)
Sites
96

Conditions

As the registry lists them; a condition with its own page is linked.

angioimmunoblastic t-cell lymphoma, enteropathy-associated t-cell lymphoma, follicular t-cell lymphoma, mature t-cell and nk-cell non-hodgkin lymphoma, monomorphic epitheliotropic intestinal t-cell lymphoma, nodal peripheral t-cell lymphoma with tfh phenotype, peripheral t-cell lymphoma, not otherwise specified